All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Moderna files for approval of mRNA-1010 seasonal influenza vaccine for adults aged 50 and older
Vaccine, infectious disease, mRNA vaccine, influenza, respiratory disease - Read more

GSK's Nucala (mepolizumab) wins China approval for chronic obstructive pulmonary disease following Ph3 trials
Antibody, respiratory, monoclonal antibody, COPD, IL-5 inhibitor, eosinophilic phenotype - Read more

Idorsia's JERAYGO (aprocitentan) wins Health Canada approval for resistant hypertension treatment targeting endothelin receptors
Small molecule, cardiovascular, resistant hypertension, endothelin receptor antagonist, combination therapy - Read more

THE GOOD
Business Development & Partnerships

Sanofi, Earendil Labs partner on AI-driven bispecific autoimmune programs, $160M upfront, $2.5B potential
Research collaboration, autoimmune, AI/ML, bispecific antibody, milestone payments - Read more

Insilico Medicine, Hisun Pharmaceutical collaboration yields first AI-driven preclinical candidate in under a year
Research collaboration, AI/ML, drug discovery, small molecule - Read more

Servier, Insilico Medicine partner on AI-driven oncology drug discovery, $32M upfront, $888M total
Research collaboration, oncology, AI/ML, drug discovery, milestone payments - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps = Fast Deployment + Lower Cost

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

Incyte's Monjuvi (tafasitamab) shows Ph3 success in first-line diffuse large B-cell lymphoma, FDA filing planned
Antibody, cancer, monoclonal antibody, diffuse large B-cell lymphoma, combination therapy, first-line treatment - Read more

BioInvent's BI-1808 combination with Keytruda shows 24% response rate in Ph2a recurrent ovarian cancer trial
Antibody, cancer, monoclonal antibody, ovarian cancer, combination therapy, PD-1 inhibitor - Read more

Crinetics' atumelnant achieves 67% androstenedione reduction in Ph2 congenital adrenal hyperplasia study
Small molecule, metabolic, ACTH receptor antagonist, congenital adrenal hyperplasia, androstenedione reduction - Read more

Neumora Therapeutics reports positive Ph1b results for NMRA-511 vasopressin 1a receptor antagonist in Alzheimer's disease agitation
Small molecule, neurological, vasopressin 1a receptor antagonist, Alzheimer's disease, agitation - Read more

MetaVia reports 9% weight loss with DA-1726 dual glucagon-like peptide-1/glucagon agonist in Ph1 obesity trial
Small molecule, metabolic, dual agonist, obesity, GLP-1 receptor, glucagon receptor - Read more

Zenas BioPharma's obexelimab hits Ph3 targets in IgG4-related disease, reducing flare risk by 56%
Antibody, autoimmune, monoclonal antibody, IgG4-related disease, CD19 target - Read more

THE GOOD
Fundraises

Aktis Oncology aims for $209M IPO, developing miniprotein radiopharmaceuticals for cancer
Oncology, radiopharmaceutical, miniprotein, clinical-stage, platform technology - Read more

Comanche Biopharma raises $40M funding, developing siRNA treatment for preeclampsia
siRNA, preeclampsia, clinical-stage, women's health - Read more [Paywall]

Crinetics Pharmaceuticals raises $350M public offering, endocrine therapeutics commercialization and development
Endocrine diseases, small molecule, clinical-stage, commercialization - Read more

THE GOOD
Investments

Daiichi Sankyo plans $1.9B global Enhertu manufacturing investments across Japan, U.S., Germany, China
Antibody-drug conjugate, oncology, strategic, major transaction, operational - Read more

THE GOOD
Marketing

FUJIFILM Irvine Scientific rebrands to FUJIFILM Biosciences to better align with company's 55-year history
Rebranding, cell culture, manufacturing, life sciences - Read more

THE GOOD
Product Launches

Novo Nordisk launches oral Wegovy in US at $149 monthly out-of-pocket price, shares rise 2.6%
GLP-1 agonist, metabolic disease, competitive, revenue impact - Read more

THE GOOD
Regulatory

Sanofi's Tzield (teplizumab) receives FDA priority review for stage 2 type 1 diabetes in young children
Antibody, autoimmune, monoclonal antibody, type 1 diabetes, pediatric population, CD3 target - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Business Development & Partnerships

TME Pharma, Singapore Eye Research Institute terminate eye drug NOX-E36 collaboration partnership
Research collaboration, ophthalmology, small molecule, partnership termination - Read more

THE UGLY
Regulatory

CDC removes six vaccines from childhood recommendation list following RFK Jr.'s monthlong review
Vaccines, infectious disease, regulatory, operational - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here